RxDoctor Payments Data

Jason Zimmerman, DO

Emergency Medicine · Brooklyn, NYNPI 1073871067

Payments from drug & device makers

$301in general payments, 2019–2025

Across 11 payments — averaging $27.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$121
  • Smith+Nephew$35
  • Eisai Inc.$30
  • SK Life Science, Inc.$30
  • Johnson & Johnson$25
  • Mylan Specialty L.p.$23
  • plus $37 from 2 others

What the payments were for

  • Food & beverage$301100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$301 in reported general payments places this provider in the 85th percentile of 4,167 emergency medicine providers in New York.

See all emergency medicine providers in New York

Medicare billing

Part B allowed, 2024
$85,555
Medicare patients
417
Services billed
1,393

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban540$160,568
NuplazidPimavanserin Tartrate26$64,914
JanuviaSitagliptin Phosphate167$47,114
LinzessLinaclotide71$40,898
TradjentaLinagliptin130$34,364
CreonLipase/Protease/Amylase37$31,178
JardianceEmpagliflozin87$26,153
RexultiBrexpiprazole32$23,051
SantylCollagenase Clostridium Hist.33$21,639
KonvomepOmeprazole/Sodium Bicarbonate56$20,986
EntrestoSacubitril/Valsartan57$19,677
ZenpepLipase/Protease/Amylase20$17,970
FarxigaDapagliflozin Propanediol54$15,990
OzempicSemaglutide13$13,432
AustedoDeutetrabenazine11$13,187

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$121$64,91426 claims
Smith+NephewSantyl$35$21,63933 claims
Johnson & JohnsonXarelto, Procrit$25$16,93950 claims
Teva Pharmaceuticals USA, Inc.Austedo$22$13,18711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,167 emergency medicine providers in New York.

Other emergency medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →